ホーム › マントル細胞リンパ腫 › カリフォルニア州
カリフォルニア州におけるマントル細胞リンパ腫の臨床試験
カリフォルニア州内の拠点で、マントル細胞リンパ腫に関する29件の研究が参加者を募集しています。
カリフォルニア州内の都市
公式研究テキスト（英語）
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Tower Cancer Research Foundation, Beverly Hills
- Cedars-Sinai Medical Center, Los Angeles
被験者募集中第3相
60歳以上 · 全性別 · 2026/10/02更新 · NCT05976763Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- University of California, Davis, Davis
- University of California, Los Angeles, Los Angeles
- University of California, San Diego, San Diego
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06252675A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06542250A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Ucsf Fresno, Fresno
- Kaiser Permanente Southern California, Irvine
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- Stanford Cancer Center, Stanford
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06553872A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- City of Hope Comprehensive Cancer Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07003295A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07691606AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Cedars-Sinai Medical Center, Los Angeles
被験者募集中第1相
18歳〜85歳 · 全性別 · 2026/08/10更新 · NCT05887167Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06675123A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Los Angele, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- City of Hope, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/24更新 · NCT07121946DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/22更新 · NCT04545762Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- City of Hope Medical center, Duarte
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT03523975Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/20更新 · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- 他1件
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/13更新 · NCT06572618Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/23更新 · NCT05432635Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/05更新 · NCT06054776AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- City of Hope Medical Center, Duarte
- Stanford University, Stanford
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/20更新 · NCT05370430SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- 他3件
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Stanford Cancer Center, Palo Alto
被験者募集中観察研究
18歳以上 · 全性別 · 2024/08/22更新 · NCT05255354ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。